Adding a second HER2 targeted medicine may lower chance of invasive breast cancer

Targeted sequencing in endocrine refractory breast cancer

Treating BRCA breast cancer with PARP inhibition

Relieving spinal cord compression symptoms with a single radiation treatment

Halving duration of ADT for high risk prostate cancer patients

Findings of a phase I/II study of nivolumab in patients with virus-associated tumours

New personalised therapies for lung cancer

Nivolumab and ipilimumab for metastatic sarcoma

Selumetinib in children with recurrent or refractory low-grade glioma

Phase III results of olaparib for BRCA breast cancer

Global health initiative oncology

Tivantinib as second line therapy for high-MET HCC